Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Dry Eye, A Variety Of Mechanisms Pursue Established Therapies

Executive Summary

Market Snapshot: Kala's Phase III nanoparticle along with Aldeyra's aldehyde trap drug and Ocugen's brimonidine/steroid combo, both in Phase II, are among the candidates pursuing Restasis and Xiidra.

You may also be interested in...



Kala’s Third Phase III Trial Should Line Up Approval In Dry Eye

Data showing that endpoints were met for both signs and symptoms of dry eye disease should position Kala’s KRI-121 for US approval. The company hopes to differentiate with short-term flare treatment.

Aldeyra One Step Closer To Joint Treatment For Allergic Conjunctivitis, Dry Eye Disease

With Phase III programs on similar timelines, Aldeyra hopes it may be able to file for both indications concurrently for its aldehyde trap candidate reproxalap.

Deal Watch: Xencor Adds New Bispecific Partner In Agreement With Genentech

Genentech will pay $120m up front to co-develop Xencor’s preclinical IL-15 candidate; deal also includes IL-15 R&D. Taiho licenses lung cancer candidate to Cullinan; Celgene and Triphase partner again.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC100033

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel